Asterias Biotherapeutics (AST) Getting Positive News Coverage, Report Finds

Media coverage about Asterias Biotherapeutics (NYSE:AST) has been trending positive this week, according to Alpha One Sentiment. Alpha One, a subsidiary of Accern, identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a news sentiment score of 0.25 on Alpha One’s scale. Alpha One also gave news stories about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

These are some of the news stories that may have impacted AlphaOne Sentiment’s scoring:

Insider Buying and Selling by Quarter for Asterias Biotherapeutics (NYSE:AST)

Several equities analysts have issued reports on the company. HC Wainwright set a $12.00 price objective on Asterias Biotherapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. Laidlaw started coverage on Asterias Biotherapeutics in a research note on Tuesday, April 4th. They issued a “buy” rating and a $12.00 target price for the company. Finally, Zacks Investment Research cut Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, April 3rd.

Shares of Asterias Biotherapeutics (NYSE:AST) opened at 3.20 on Friday. Asterias Biotherapeutics has a 52 week low of $2.30 and a 52 week high of $5.80. The company’s 50 day moving average price is $3.27 and its 200-day moving average price is $3.73. The firm’s market capitalization is $157.64 million.

Asterias Biotherapeutics (NYSE:AST) last announced its earnings results on Tuesday, March 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. Asterias Biotherapeutics had a negative net margin of 312.79% and a negative return on equity of 58.31%. The company had revenue of $1.75 million for the quarter, compared to analysts’ expectations of $2.81 million. On average, equities research analysts expect that Asterias Biotherapeutics will post ($0.72) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Asterias Biotherapeutics (AST) Getting Positive News Coverage, Report Finds” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://transcriptdaily.com/2017/06/17/asterias-biotherapeutics-ast-given-news-sentiment-rating-of-0-25-updated.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply